A new paradigm for diabetes and obesity: the hepatic insulin sensitizing substance (HISS) hypothesis

被引:55
作者
Lautt, WW [1 ]
机构
[1] Univ Manitoba, Fac Med, Dept Pharmacol & Therapeut, Winnipeg, MB R3E 0T6, Canada
关键词
insulin resistance; obesity; hypertension; diabetes; feeding;
D O I
10.1254/jphs.95.9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The glucose disposal effect of insulin after a meal is accounted for in approximately equal measure by the direct action of insulin and the action of HISS (hepatic insulin sensitizing substance) released from the liver and acting on skeletal muscle to stimulate glucose storage as glycogen. The ability of insulin to cause HISS release is determined by hepatic parasympathetic nerves. Eliminating the parasympathetic signal by surgical denervation of the liver or by blockade of hepatic muscarinic receptors, hepatic nitric oxide synthase, or hepatic cyclooxygenase results in insulin resistance that can be accounted for by the absence of HISS action and is referred to as HISS-dependent insulin resistance (HDIR). Animal models in which the insulin resistance has been shown to be HDIR includes the spontaneously hypertensive rat, sucrose fed rats, animals with liver disease, adult offspring of fetal alcohol exposure, acute stress, and ageing. We suggest that HDIR accounts for the major metabolic disturbances in type 2 diabetes, including the postprandial hyperglycemia that results in the majority of pathologies related to diabetes. The observation of meal-induced insulin sensitization (MIS) and the role of HISS allows for consideration of a new paradigm relating meal processing, diabetes, obesity, and insulin resistance. New diagnostic approaches and therapeutic targets are described.
引用
收藏
页码:9 / 17
页数:9
相关论文
共 43 条
  • [1] Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes
    Avignon, A
    Radauceanu, A
    Monnier, L
    [J]. DIABETES CARE, 1997, 20 (12) : 1822 - 1826
  • [2] Borch-Johnsen K, 1999, LANCET, V354, P617
  • [3] Biochemistry and molecular cell biology of diabetic complications
    Brownlee, M
    [J]. NATURE, 2001, 414 (6865) : 813 - 820
  • [4] Correia NC, 2002, P W PHARMACOL SOC, V45, P57
  • [5] DALMEIDA MS, 2002, CAN J DIABETES, V2, P301
  • [6] DALMEIDA MS, 2003, CAN J DIABETES, V27, P332
  • [7] Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population:: the Hoorn Study
    de Vegt, F
    Dekker, JM
    Ruhé, HG
    Stehouwer, CDA
    Nijpels, G
    Bouter, LM
    Heine, RJ
    [J]. DIABETOLOGIA, 1999, 42 (08) : 926 - 931
  • [8] The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus
    Del Prato, S
    Tiengo, A
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2001, 17 (03) : 164 - 174
  • [9] Screening for type 2 diabetes
    Engelgau, MM
    Narayan, KMV
    Herman, WH
    [J]. DIABETES CARE, 2000, 23 (10) : 1563 - 1580
  • [10] Hepatic glutathione and nitric oxide are critical for hepatic insulin-sensitizing substance action
    Guarino, MP
    Afonso, RA
    Raimundo, N
    Raposo, JF
    Macedo, MP
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2003, 284 (04): : G588 - G594